GGrantIndex
← Leaderboards

Andrew B Norman

University Of Cincinnati

$25,974,738
Attributed
$25,974,738
Total exposure
6
Grants
5
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $6.6M · FY200521
$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21

Funding mix

By agency

NIH$29,011,203 · 7

By mechanism

U01$18,790,564 · 3
DP1$3,800,342 · 1
U19$3,444,930 · 2
R44$2,975,367 · 1

Top collaborators

No co-investigators on record.

Most similar at University Of Cincinnati

Same institution · by research overlap

Others in their field

Top investigators on “Cocaine

Research focus

CocaineBrainMolecularToxicologySafetyRattusRelapseCommercializationMonoclonal AntibodiesSpecificityPre-ClinicalAntibodiesAffinityImmunotherapyCocaine AbuseMultidisciplinaryPeripheralProductionIn VivoHuman TissuePreventProtocols DocumentationCross ReactivityMeetings

Grant awards (25)

First-In-Human Study of a Humanized Anti-Cocaine Monoclonal Antibody$1,777,952
U01 · FY2021 · DA · contact PI
IND-Enabling Pre-Clinical Studies to Accelerate the Clinical Development of a Humanized Anti-Cocaine Monoclonal Antibody$1,108,943
U01 · FY2021 · DA · contact PI
First-In-Human Study of a Humanized Anti-Cocaine Monoclonal Antibody$1,925,827
U01 · FY2020 · DA · contact PI
IND-Enabling Pre-Clinical Studies to Accelerate the Clinical Development of a Humanized Anti-Cocaine Monoclonal Antibody$1,151,637
U01 · FY2020 · DA · contact PI
First-In-Human Study of a Humanized Anti-Cocaine Monoclonal Antibody$4,770,702
U01 · FY2019 · DA · contact PI
IND-Enabling Pre-Clinical Studies to Accelerate the Clinical Development of a Humanized Anti-Cocaine Monoclonal Antibody$1,796,316
U01 · FY2019 · DA · contact PI
Advancing the Development of a Humanized Anti-cocaine Monoclonal Antibody$2,086,019
U01 · FY2017 · DA · contact PI
Advancing the Development of a Humanized Anti-cocaine Monoclonal Antibody$2,065,159
U01 · FY2016 · DA · contact PI
Advancing the Development of a Humanized Anti-cocaine Monoclonal Antibody$2,108,009
U01 · FY2015 · DA · contact PI
A Human Antibody as an Immunotherapy for Cocaine Abuse (DP1)$761,450
DP1 · FY2014 · DA · contact PI
A Human Antibody as an Immunotherapy for Cocaine Abuse (DP1)$730,992
DP1 · FY2013 · DA · contact PI
A Human Antibody as an Immunotherapy for Cocaine Abuse (DP1)$761,450
DP1 · FY2012 · DA · contact PI
A Human Antibody as an Immunotherapy for Cocaine Abuse (DP1)$761,450
DP1 · FY2011 · DA · contact PI
A Human Antibody as an Immunotherapy for Cocaine Abuse (DP1)$785,000
DP1 · FY2010 · DA · contact PI
A Human Antibody as an Immunotherapy for Cocaine Abuse$133,684
R44 · FY2009 · DA · contact PI
A Human Antibody as an Immunotherapy for Cocaine Abuse$922,721
R44 · FY2008 · DA · contact PI
A Human Antibody as an Immunotherapy for Cocaine Abuse$911,120
R44 · FY2007 · DA · contact PI
A Human Antibody as an Immunotherapy for Cocaine Abuse$444,299
R44 · FY2006 · DA · contact PI
A Human Antibody as an Immunotherapy for Cocaine Abuse$436,401
R44 · FY2005 · DA
A Human Antibody as an Immunotherapy for Cocaine Abuse$127,142
R44 · FY2004 · DA
PASSIVE IMMUNITY TO COCAINE USING NOVEL HUMAN ANTIBODIES$650,000
U19 · FY2003 · DA
PASSIVE IMMUNITY TO COCAINE USING NOVEL HUMAN ANTIBODIES$1,671,351
U19 · FY2001 · DA
PRE-CLINICAL ANIMAL TESTING$0
U19 · FY2001 · DA
PASSIVE IMMUNITY TO COCAINE USING NOVEL HUMAN ANTIBODIES$715,114
U19 · FY2000 · DA
PRE-CLINICAL ANIMAL TESTING$408,465
U19 · FY2000 · DA